Cytokinetics sues Bristol Myers, MyoKardia seeking ruling on MYQORZO patent dispute
CYTK•Company seeks to invalidate patent claims
Cytokinetics also asks the court to invalidate the patent claims, citing uncertainty over the outcome of litigation.
The filing requests an injunction to stop the defendants from threatening or bringing patent suits tied to MYQORZO. Cytokinetics demanded a jury trial and is seeking costs and attorneys' fees under 35 U.S.C. § 285.
Cytokinetics files patent complaint in Delaware
Cytokinetics filed a complaint on Aug. 13, 2026 in U.S. District Court in Delaware against Bristol-Myers Squibb and MyoKardia.
The suit seeks a declaratory judgment of non-infringement of U.S. Patent No. 12,616,697, which covers MYQORZO (aficamten).
